Indivior (LON:INDV – Get Free Report) had its price target lifted by analysts at Morgan Stanley from GBX 2,500 ($32.10) to GBX 2,700 ($34.66) in a note issued to investors on Thursday, FlyOnTheWall reports. Morgan Stanley’s price objective suggests a potential upside of 51.13% from the stock’s previous close. Separately, Jefferies Financial Group reissued a […]
By Elena Vardon C4X Discovery Holdings on Tuesday said it is selling the proprietary rights to its oral Orexin-1 receptor antagonist for substance use.
Indivior (NASDAQ:INDV – Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.17, MarketWatch Earnings reports. The firm had revenue of $276.00 million during the quarter, compared to analysts’ expectations of $250.00 million. During the same period […]
By Joe Hoppe Indivior said Thursday that pretax profit and revenue for the second quarter rose on strong sales volume growth, and raised its full-year.
Northland Securities began coverage on shares of Indivior (NASDAQ:INDV – Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm issued an outperform rating and a $35.00 price target on the stock. Indivior Trading Up 0.3 % Shares of INDV stock opened at $23.34 on Thursday. The company has a market cap of […]